Skip to main content
PMC home page
The Journal of Cell Biology logoLink to The Journal of Cell Biology
. 1996 Dec 2;135(6):1889–1898. doi: 10.1083/jcb.135.6.1889

Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo

PMCID: PMC2133968  PMID: 8991099

Abstract

Human malignant melanoma is notoriously resistant to pharmacological modulation. We describe here for the first time that the synthetic retinoid CD437 has a strong dose-dependent antiproliferative effect on human melanoma cells (IC50: 5 x 10(-6) M) via the induction of programmed cell death, as judged by analysis of cell morphology, electron microscopical features, and DNA fragmentation. Programmed cell death was preceded by a strong activation of the AP-1 complex in CD437- treated cells as demonstrated by gel retardation and chloramphenicol transferase (CAT) assays. Northern blot analysis showed a time- dependent increase in the expression of c-fos and c-jun encoding components of AP-1, whereas bcl-2 and p53 mRNA levels remained constant. CD437 also exhibited a strong growth inhibitory effect on MeWo melanoma cells in a xenograft model. In tissue sections of CD437- treated MeWo tumors from these animals, apoptotic melanoma cells and c- fos overexpressing cells were colocalized by TdT-mediated deoxyuridine triphosphate-digoxigenin nick end labeling (TUNEL) staining and in situ hybridization. Taken together, this report identifies CD437 as a retinoid that activates and upregulates the transcription factor AP-1, leading eventually to programmed cell death of exposed human melanoma cells in vitro and in vivo. Further studies are needed to evaluate whether synthetic retinoids such as CD437 represent a new class of retinoids, which may open up new ways to a more effective therapy of malignant melanoma.

Full Text

The Full Text of this article is available as a PDF (4.8 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alles A. J., Sulik K. K. Retinoic acid-induced spina bifida: evidence for a pathogenetic mechanism. Development. 1990 Jan;108(1):73–81. doi: 10.1242/dev.108.Supplement.73. [DOI] [PubMed] [Google Scholar]
  2. Artuc M., Nürnberg W., Czarnetzki B. M., Schadendorf D. Characterization of gene regulatory elements for selective gene expression in human melanoma cells. Biochem Biophys Res Commun. 1995 Aug 15;213(2):699–705. doi: 10.1006/bbrc.1995.2187. [DOI] [PubMed] [Google Scholar]
  3. Auwerx J., Sassone-Corsi P. AP-1 (Fos-Jun) regulation by IP-1: effect of signal transduction pathways and cell growth. Oncogene. 1992 Nov;7(11):2271–2280. [PubMed] [Google Scholar]
  4. Baker S. J., Markowitz S., Fearon E. R., Willson J. K., Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 1990 Aug 24;249(4971):912–915. doi: 10.1126/science.2144057. [DOI] [PubMed] [Google Scholar]
  5. Bernard B. A., Bernardon J. M., Delescluse C., Martin B., Lenoir M. C., Maignan J., Charpentier B., Pilgrim W. R., Reichert U., Shroot B. Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor gamma. Biochem Biophys Res Commun. 1992 Jul 31;186(2):977–983. doi: 10.1016/0006-291x(92)90842-9. [DOI] [PubMed] [Google Scholar]
  6. Bollag W., Holdener E. E. Retinoids in cancer prevention and therapy. Ann Oncol. 1992 Jul;3(7):513–526. doi: 10.1093/oxfordjournals.annonc.a058252. [DOI] [PubMed] [Google Scholar]
  7. Buttyan R., Zakeri Z., Lockshin R., Wolgemuth D. Cascade induction of c-fos, c-myc, and heat shock 70K transcripts during regression of the rat ventral prostate gland. Mol Endocrinol. 1988 Jul;2(7):650–657. doi: 10.1210/mend-2-7-650. [DOI] [PubMed] [Google Scholar]
  8. Chen J. Y., Penco S., Ostrowski J., Balaguer P., Pons M., Starrett J. E., Reczek P., Chambon P., Gronemeyer H. RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. EMBO J. 1995 Mar 15;14(6):1187–1197. doi: 10.1002/j.1460-2075.1995.tb07102.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chen S. C., Curran T., Morgan J. I. Apoptosis in the nervous system: new revelations. J Clin Pathol. 1995 Jan;48(1):7–12. doi: 10.1136/jcp.48.1.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Colotta F., Polentarutti N., Sironi M., Mantovani A. Expression and involvement of c-fos and c-jun protooncogenes in programmed cell death induced by growth factor deprivation in lymphoid cell lines. J Biol Chem. 1992 Sep 15;267(26):18278–18283. [PubMed] [Google Scholar]
  11. Devary Y., Gottlieb R. A., Lau L. F., Karin M. Rapid and preferential activation of the c-jun gene during the mammalian UV response. Mol Cell Biol. 1991 May;11(5):2804–2811. doi: 10.1128/mcb.11.5.2804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Engelberg D., Klein C., Martinetto H., Struhl K., Karin M. The UV response involving the Ras signaling pathway and AP-1 transcription factors is conserved between yeast and mammals. Cell. 1994 May 6;77(3):381–390. doi: 10.1016/0092-8674(94)90153-8. [DOI] [PubMed] [Google Scholar]
  13. Estus S., Zaks W. J., Freeman R. S., Gruda M., Bravo R., Johnson E. M., Jr Altered gene expression in neurons during programmed cell death: identification of c-jun as necessary for neuronal apoptosis. J Cell Biol. 1994 Dec;127(6 Pt 1):1717–1727. doi: 10.1083/jcb.127.6.1717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Evans R. M. The steroid and thyroid hormone receptor superfamily. Science. 1988 May 13;240(4854):889–895. doi: 10.1126/science.3283939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fanjul A., Dawson M. I., Hobbs P. D., Jong L., Cameron J. F., Harlev E., Graupner G., Lu X. P., Pfahl M. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature. 1994 Nov 3;372(6501):107–111. doi: 10.1038/372107a0. [DOI] [PubMed] [Google Scholar]
  16. Hagmeyer B. M., Angel P., van Dam H. Modulation of AP-1/ATF transcription factor activity by the adenovirus-E1A oncogene products. Bioessays. 1995 Jul;17(7):621–629. doi: 10.1002/bies.950170708. [DOI] [PubMed] [Google Scholar]
  17. Ho V. C., Sober A. J. Therapy for cutaneous melanoma: an update. J Am Acad Dermatol. 1990 Feb;22(2 Pt 1):159–176. doi: 10.1016/0190-9622(90)70019-e. [DOI] [PubMed] [Google Scholar]
  18. Hoal E., Wilson E. L., Dowdle E. B. Variable effects of retinoids on two pigmenting human melanoma cell lines. Cancer Res. 1982 Dec;42(12):5191–5195. [PubMed] [Google Scholar]
  19. Horie M., Broxmeyer H. E. The combination of Steel factor and GM-CSF blocks apoptosis induced by retinoic acid and upregulates AP-1 in a human growth factor-dependent cell line. Exp Hematol. 1995 Feb;23(2):168–173. [PubMed] [Google Scholar]
  20. Hughes P., Dragunow M. Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system. Pharmacol Rev. 1995 Mar;47(1):133–178. [PubMed] [Google Scholar]
  21. Kamei Y., Xu L., Heinzel T., Torchia J., Kurokawa R., Gloss B., Lin S. C., Heyman R. A., Rose D. W., Glass C. K. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell. 1996 May 3;85(3):403–414. doi: 10.1016/s0092-8674(00)81118-6. [DOI] [PubMed] [Google Scholar]
  22. Kastner P., Mark M., Chambon P. Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? Cell. 1995 Dec 15;83(6):859–869. doi: 10.1016/0092-8674(95)90202-3. [DOI] [PubMed] [Google Scholar]
  23. Kolde G., Knop J. Ultrastructural morphometry of epidermal Langerhans' cells: introduction of a simple method for a comprehensive quantitative analysis of the cells. Arch Dermatol Res. 1986;278(4):298–301. doi: 10.1007/BF00407741. [DOI] [PubMed] [Google Scholar]
  24. Kurie J. M., Lippman S. M., Hong W. K. Potential of retinoids in cancer prevention. Cancer Treat Rev. 1994 Jan;20(1):1–10. doi: 10.1016/0305-7372(94)90008-6. [DOI] [PubMed] [Google Scholar]
  25. Li J. J., Dong Z., Dawson M. I., Colburn N. H. Inhibition of tumor promoter-induced transformation by retinoids that transrepress AP-1 without transactivating retinoic acid response element. Cancer Res. 1996 Feb 1;56(3):483–489. [PubMed] [Google Scholar]
  26. Lotan R. Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochim Biophys Acta. 1980 Mar 12;605(1):33–91. doi: 10.1016/0304-419x(80)90021-9. [DOI] [PubMed] [Google Scholar]
  27. Mangelsdorf D. J., Evans R. M. The RXR heterodimers and orphan receptors. Cell. 1995 Dec 15;83(6):841–850. doi: 10.1016/0092-8674(95)90200-7. [DOI] [PubMed] [Google Scholar]
  28. Marti A., Jehn B., Costello E., Keon N., Ke G., Martin F., Jaggi R. Protein kinase A and AP-1 (c-Fos/JunD) are induced during apoptosis of mouse mammary epithelial cells. Oncogene. 1994 Apr;9(4):1213–1223. [PubMed] [Google Scholar]
  29. Martin S. J., Green D. R. Apoptosis as a goal of cancer therapy. Curr Opin Oncol. 1994 Nov;6(6):616–621. doi: 10.1097/00001622-199411000-00015. [DOI] [PubMed] [Google Scholar]
  30. Meyskens F. L., Jr, Fuller B. B. Characterization of the effects of different retinoids on the growth and differentiation of a human melanoma cell line and selected subclones. Cancer Res. 1980 Jul;40(7):2194–2196. [PubMed] [Google Scholar]
  31. Nürnberg W., Artuc M., Vorbrueggen G., Kalkbrenner F., Moelling K., Czarnetzki B. M., Schadendorf D. Nuclear proto-oncogene products transactivate the human papillomavirus type 16 promoter. Br J Cancer. 1995 May;71(5):1018–1024. doi: 10.1038/bjc.1995.196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Pfahl M. Nuclear receptor/AP-1 interaction. Endocr Rev. 1993 Oct;14(5):651–658. doi: 10.1210/edrv-14-5-651. [DOI] [PubMed] [Google Scholar]
  33. Piacentini M., Fesus L., Farrace M. G., Ghibelli L., Piredda L., Melino G. The expression of "tissue" transglutaminase in two human cancer cell lines is related with the programmed cell death (apoptosis). Eur J Cell Biol. 1991 Apr;54(2):246–254. [PubMed] [Google Scholar]
  34. Piechaczyk M., Blanchard J. M. c-fos proto-oncogene regulation and function. Crit Rev Oncol Hematol. 1994 Oct;17(2):93–131. doi: 10.1016/1040-8428(94)90021-3. [DOI] [PubMed] [Google Scholar]
  35. Schadendorf D., Makki A., Stahr C., van Dyck A., Wanner R., Scheffer G. L., Flens M. J., Scheper R., Henz B. M. Membrane transport proteins associated with drug resistance expressed in human melanoma. Am J Pathol. 1995 Dec;147(6):1545–1552. [PMC free article] [PubMed] [Google Scholar]
  36. Schadendorf D., Möller A., Algermissen B., Worm M., Sticherling M., Czarnetzki B. M. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol. 1993 Sep 1;151(5):2667–2675. [PubMed] [Google Scholar]
  37. Schreiber M., Baumann B., Cotten M., Angel P., Wagner E. F. Fos is an essential component of the mammalian UV response. EMBO J. 1995 Nov 1;14(21):5338–5349. doi: 10.1002/j.1460-2075.1995.tb00218.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Schüle R., Rangarajan P., Kliewer S., Ransone L. J., Bolado J., Yang N., Verma I. M., Evans R. M. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell. 1990 Sep 21;62(6):1217–1226. doi: 10.1016/0092-8674(90)90397-w. [DOI] [PubMed] [Google Scholar]
  39. Schüle R., Rangarajan P., Yang N., Kliewer S., Ransone L. J., Bolado J., Verma I. M., Evans R. M. Retinoic acid is a negative regulator of AP-1-responsive genes. Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6092–6096. doi: 10.1073/pnas.88.14.6092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Shao Z. M., Dawson M. I., Li X. S., Rishi A. K., Sheikh M. S., Han Q. X., Ordonez J. V., Shroot B., Fontana J. A. p53 independent G0/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene. 1995 Aug 3;11(3):493–504. [PubMed] [Google Scholar]
  41. Smeyne R. J., Vendrell M., Hayward M., Baker S. J., Miao G. G., Schilling K., Robertson L. M., Curran T., Morgan J. I. Continuous c-fos expression precedes programmed cell death in vivo. Nature. 1993 May 13;363(6425):166–169. doi: 10.1038/363166a0. [DOI] [PubMed] [Google Scholar]
  42. Smith M. A., Parkinson D. R., Cheson B. D., Friedman M. A. Retinoids in cancer therapy. J Clin Oncol. 1992 May;10(5):839–864. doi: 10.1200/JCO.1992.10.5.839. [DOI] [PubMed] [Google Scholar]
  43. Trede N. S., Geha R. S., Chatila T. Transcriptional activation of IL-1 beta and tumor necrosis factor-alpha genes by MHC class II ligands. J Immunol. 1991 Apr 1;146(7):2310–2315. [PubMed] [Google Scholar]
  44. Yang-Yen H. F., Zhang X. K., Graupner G., Tzukerman M., Sakamoto B., Karin M., Pfahl M. Antagonism between retinoic acid receptors and AP-1: implications for tumor promotion and inflammation. New Biol. 1991 Dec;3(12):1206–1219. [PubMed] [Google Scholar]

Articles from The Journal of Cell Biology are provided here courtesy of The Rockefeller University Press

RESOURCES